Target Price | $506.92 |
Price | $474.62 |
Potential | 6.81% |
Number of Estimates | 26 |
26 Analysts have issued a price target Vertex Pharmaceuticals 2026 . The average Vertex Pharmaceuticals target price is $506.92. This is 6.81% higher than the current stock price. The highest price target is $615.00 29.58% , the lowest is $330.00 30.47% . | |
A rating was issued by 35 analysts: 20 Analysts recommend Vertex Pharmaceuticals to buy, 13 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Vertex Pharmaceuticals stock has an average upside potential 2026 of 6.81% . Most analysts recommend the Vertex Pharmaceuticals stock at Purchase. |
28 Analysts have issued a sales forecast Vertex Pharmaceuticals 2025 . The average Vertex Pharmaceuticals sales estimate is $12.0b . This is 8.99% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $12.5b 13.38% , the lowest is $11.8b 6.97% .
This results in the following potential growth metrics:
2024 | $11.0b | 11.64% |
---|---|---|
2025 | $12.0b | 8.99% |
2026 | $13.2b | 9.89% |
2027 | $14.3b | 8.95% |
2028 | $15.5b | 8.33% |
2029 | $17.2b | 10.80% |
8 Analysts have issued an Vertex Pharmaceuticals EBITDA forecast 2025. The average Vertex Pharmaceuticals EBITDA estimate is $5.6b . This is 22,876.47% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.1b 24,966.71% , the lowest is $4.8b 19,847.65% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.6b | 2.39% |
---|---|---|
2025 | $5.6b | 21.80% |
2026 | $6.8b | 21.99% |
2027 | $7.5b | 10.65% |
2028 | $8.2b | 9.58% |
2029 | $9.1b | 10.19% |
2024 | 41.56% | 8.29% |
---|---|---|
2025 | 46.44% | 11.74% |
2026 | 51.56% | 11.02% |
2027 | 52.36% | 1.55% |
2028 | 52.96% | 1.15% |
2029 | 52.67% | 0.55% |
19 Vertex Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Vertex Pharmaceuticals net profit estimate is $4.1b . This is 831.45% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.7b 927.27% , the lowest is $3.6b 734.55% .
This results in the following potential growth metrics and future Net Margins:
2024 | $-534m | 114.97% |
---|---|---|
2025 | $4.1b | 873.65% |
2026 | $4.8b | 15.25% |
2027 | $5.2b | 9.97% |
2028 | $6.3b | 19.60% |
2029 | $6.8b | 8.84% |
2024 | -4.87% | 113.41% |
---|---|---|
2025 | 34.53% | 809.70% |
2026 | 36.22% | 4.89% |
2027 | 36.56% | 0.94% |
2028 | 40.36% | 10.39% |
2029 | 39.65% | 1.76% |
19 Analysts have issued a Vertex Pharmaceuticals forecast for earnings per share. The average Vertex Pharmaceuticals EPS is $16.09 . This is 831.36% higher than earnings per share in the financial year 2024. The highest EPS forecast is $18.20 927.27% , the lowest is $13.96 734.55% .
This results in the following potential growth metrics and future valuations:
2024 | $-2.08 | 114.97% |
---|---|---|
2025 | $16.09 | 873.56% |
2026 | $18.55 | 15.29% |
2027 | $20.39 | 9.92% |
2028 | $24.39 | 19.62% |
2029 | $26.55 | 8.86% |
Current | -215.57 | 816.42% |
---|---|---|
2025 | 29.49 | 113.68% |
2026 | 25.59 | 13.22% |
2027 | 23.27 | 9.07% |
2028 | 19.46 | 16.37% |
2029 | 17.88 | 8.12% |
Based on analysts' sales estimates for 2025, the Vertex Pharmaceuticals stock is valued at an EV/Sales of 9.82 and an P/S ratio of 10.18 .
This results in the following potential growth metrics and future valuations:
Current | 10.70 | 7.86% |
---|---|---|
2025 | 9.82 | 8.27% |
2026 | 8.93 | 9.00% |
2027 | 8.20 | 8.22% |
2028 | 7.57 | 7.69% |
2029 | 6.83 | 9.74% |
Current | 11.10 | 1.11% |
---|---|---|
2025 | 10.18 | 8.25% |
2026 | 9.26 | 9.00% |
2027 | 8.50 | 8.22% |
2028 | 7.85 | 7.69% |
2029 | 7.08 | 9.74% |
Vertex Pharmaceuticals...
Analyst | Rating | Action | Date |
---|---|---|---|
RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Apr 01 2025 |
B of A Securities |
Buy
➜
Buy
|
Unchanged | Mar 31 2025 |
RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Feb 20 2025 |
Canaccord Genuity |
Sell
➜
Hold
|
Upgrade | Feb 12 2025 |
Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Feb 11 2025 |
HC Wainwright & Co. |
Buy
➜
Buy
|
Unchanged | Feb 11 2025 |
Needham |
Hold
➜
Hold
|
Unchanged | Feb 11 2025 |
Analyst Rating | Date |
---|---|
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Apr 01 2025 |
Unchanged
B of A Securities:
Buy
➜
Buy
|
Mar 31 2025 |
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Feb 20 2025 |
Upgrade
Canaccord Genuity:
Sell
➜
Hold
|
Feb 12 2025 |
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
Feb 11 2025 |
Unchanged
HC Wainwright & Co.:
Buy
➜
Buy
|
Feb 11 2025 |
Unchanged
Needham:
Hold
➜
Hold
|
Feb 11 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.